Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
March 09, 2018Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera
December 11, 2017Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia
November 03, 2017A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.

Complications and Management of Coagulation Disorders in Leukemia Patients
October 06, 2017[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA
October 03, 2017This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.

A Patient's Guide to Managing Symptoms of Polycythemia Vera (Fact Sheet)
September 15, 2017This fact sheet reviews common symptoms associated with polycythemia vera (PV) and how a patient may address them, along with an overview of more serious symptoms that require medical attention.

Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
August 21, 2017Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia
August 01, 2017Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera
June 30, 2017A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML
June 05, 2017A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant
May 26, 2017Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
May 26, 2017A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia
May 10, 2017Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).

Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms
May 09, 2017NCCN released its newest Clinical Practice Guidelines in Oncology. These guidelines will assist with preventive, diagnostic, and treatment decisions for patients with myelofibrosis, as well as the other myeloproliferative neoplasms, essential thrombocythemia and PV.

New Predisposition Genes for Familial Polycythemia Vera Are Identified
May 02, 2017Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.

JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
April 21, 2017Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.

Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
April 20, 2017This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN
April 20, 2017A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.

Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New Insights
April 19, 2017Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
February 24, 2017Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.

Pacritinib More Effective at Spleen Volume Reduction Than Best Available Therapy in Myelofibrosis
February 09, 2017
Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs
February 08, 2017In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.

Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera
November 21, 2016Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.

Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies
November 02, 2016Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.

Polycythemia Vera (Fact Sheet)
October 27, 2016This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.

Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
October 21, 2016The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.

Patients With MPNs, Physicians View Treatment Goals Differently
October 07, 2016Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
September 27, 2016Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |